[1]刘梓良,曹德斌.氯吡格雷联合阿托伐他汀钙治疗缺血性脑卒中患者的疗效及对神经功能的影响[J].医学信息,2021,34(17):111-113.[doi:10.3969/j.issn.1006-1959.2021.17.028]
　LIU Zi-liang,CAO De-bin.Efficacy of Clopidogrel Combined with Atorvastatin Calcium in the Treatment of Patients with Ischemic Stroke and its Effect on Neurological Function[J].Medical Information,2021,34(17):111-113.[doi:10.3969/j.issn.1006-1959.2021.17.028]
点击复制

氯吡格雷联合阿托伐他汀钙治疗缺血性脑卒中患者的疗效及对神经功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年17期
页码:
111-113
栏目:
论著
出版日期:
2021-09-01

文章信息/Info

Title:
Efficacy of Clopidogrel Combined with Atorvastatin Calcium in the Treatment of Patients with Ischemic Stroke and its Effect on Neurological Function
文章编号:
1006-1959（2021）17-0111-03
作者:
刘梓良; 曹德斌
（都昌县中医院神经内科，江西 都昌 332600）
Author(s):
LIU Zi-liang; CAO De-bin
(Department of Neurology,Duchang County Traditional Chinese Medicine Hospital,Duchang 332600,Jiangxi,China)
关键词:
缺血性脑卒中; 氯吡格雷; 阿托伐他汀钙; 炎性反应; 氧化应激; 神经功能
Keywords:
Ischemic stroke; Clopidogrel; Atorvastatin calcium; Inflammatory response; Oxidative stress; Nerve function
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2021.17.028
文献标志码:
A
摘要:
目的 探讨氯吡格雷联合阿托伐他汀钙治疗缺血性脑卒中（IS）患者的疗效及对神经功能的影响。方法 选择2019年3月-2020年10月我院就诊的IS患者200例作为研究对象，根据随机数字表法分为药物组和对照组，每组100例。对照组应用阿托伐他汀钙片治疗，药物组在对照组基础上联合氯吡格雷治疗，比较两组临床治疗疗效、血清指标[巨噬细胞游走抑制因子（MIF）、趋化素样因子1(CKLF1)、不规则趋化因子（FKN）水平]、氧化应激指标[过氧化氢酶（CAT）、丙二醛（MDA）]、神经功能及不良反应发生情况。结果 药物组临床治疗总有效率为95.00%，高于对照组的78.00%，差异有统计学意义（P＜0.05）；药物组MIF、CKLF1、FKN水平低于对照组，差异有统计学意义（P＜0.05）；药物组CAT水平高于对照组，MDA水平低于对照组，差异有统计学意义（P＜0.05）；药物组轻度神经功能缺损占比高于对照组，差异有统计学意义（P＜0.05）；药物组不良反应发生率为9.00%，与对照组的8.00%比较，差异无统计学意义（P＞0.05）。结论 氯吡格雷联合阿托伐他汀钙治疗IS患者疗效确切，可改善机体氧化应激反应，减轻神经功能损伤，且对血清MIF、CKLF1、FKN水平影响小，用药安全性高。
Abstract:
Objective To investigate the efficacy of clopidogrel combined with atorvastatin calcium in the treatment of patients with ischemic stroke (IS) and the effect on neurological function.Methods A total of 200 IS patients treated in our hospital from March 2019 to October 2020 were selected as the research objects.According to the random number table method, they were divided into drug group and control group, with 100 cases in each group.The control group was treated with atorvastatin calcium tablets, and the drug group was treated with clopidogrel on the basis of the control group.To compare the clinical treatment efficacy, serum indicators[macrophage migration inhibitory factor (MIF), chemokine-like factor 1 (CKLF1), irregular chemokine (FKN) ], oxidative stress indicators [catalase (CAT), malondialdehyde (MDA)], nerve function and occurrence of adverse reactions.Results The total effective rate of clinical treatment in the drug group was 95.00%, which was higher than 78.00% in the control group,the difference was statistically significant(P<0.05);The levels of MIF, CKLF1 and FKN in the drug group were lower than those in the control group,the difference was statistically significant (P<0.05);The CAT level of the drug group was higher than that of the control group, and the MDA level was lower than that of the control group, the difference was statistically significant (P＜0.05);The proportion of mild neurological deficits in the drug group was higher than that in the control group,the difference was statistically significant(P<0.05);The incidence of adverse reactions in the drug group was 9.00%, which was not statistically significant compared with 8.00% in the control group (P>0.05).Conclusion Clopidogrel combined with atorvastatin calcium is effective in treating IS patients.It can improve the body’s oxidative stress response, reduce nerve function damage, and has little effect on serum MIF, CKLF1, FKN levels, and has high drug safety.

参考文献/References:

[1]刘锡坚,杨思为,罗国亮,等.佛山市三水区缺血性脑卒中复发患者特征及危险因素分析[J].中国实用医药,2020,15(31):20-22. [2]刘玲.大剂量阿托伐他汀钙对急性IS患者神经功能的保护作用[J].中国实用神经疾病杂志,2019,22(10):1105-1110. [3]Deen T,Terna T,Kim E,et al.The Impact of Stroke Nurse Navigation on Patient Compliance Postdischarge[J].Rehabil Nurs,2018,43(2):65-72. [4]杜卫,李靖宇,王翠,等.IS脑微出血的危险因素及阿托伐他汀钙的治疗效果[J].贵州医科大学学报,2019,44(12):1481-1485. [5]杨伟毅,邹慧莉,胡晓辉.依达拉奉联合阿托伐他汀钙治疗IS的疗效[J].血栓与止血学,2020,26(3):436-438. [6]王琴,董均成,孙良颖.针灸联合阿托伐他汀对老年IS轻度认知障碍患者血液流变学及认知状态的影响[J].中国老年学杂志,2019,39(21):5180-5183. [7]田国英,王睿君,赵盛,等.老年IS危险因素及影像学表现[J].中国老年学杂志,2020,40(1):22-24. [8]李楠.瑞舒伐他汀与阿托伐他汀分别联合氯吡格雷治疗对缺血性脑卒中患者血清MIF CKLF1 FKN水平及神经功能的影响[J].河北医学,2019,25(12):2001-2004. [9]陈德艳,周慧,陈赟,等.强化阿托伐他汀治疗IS的疗效及其对患者血清血管性假血友病因子和血管内皮细胞钙黏蛋白水平的影响[J].海南医学,2019,30(2):163-165. [10]Lin CJ,Luo CB,Chien C,et al.Better endovascular mechanical thrombectomy outcome in atrial fibrillation patients with acute ischemic stroke:A single-center experience[J].J Chin Med Assoc,2020,83(8):756-760. [11]石蕊.阿托伐他汀联合氯吡格雷+阿司匹林双抗治疗对缺血性急性脑卒中患者再发血管事件的获益及风险分析[J].湖南师范大学学报（医学版）,2018,15(1):104-107. [12]孔辉.阿托伐他汀对老年IS患者氧化应激及脂质过氧化的影响[J].中国实用神经疾病杂志,2018,21(14):1605-1608. [13]左凤同,董爱勤,刘辉,等.阿司匹林联合硫酸氯吡格雷及阿托伐他汀对伴有脑血管狭窄的老年缺血性脑血管病患者的二级预防[J].中国老年学杂志,2016,36(10):2396-2398. [14]权素芳.高强度阿托伐他汀联合氯吡格雷对IS患者卒中相关蛋白水平及预后的影响[J].中国药物与临床,2019,19(8):1278-1281. [15]史雪霞,马骧,冶学兰.强化抗血小板与他汀类药物在IS复发高危患者二级预防的对比[J].实用临床医药杂志,2018,22(21):1-4,8.

相似文献/References:

[1]上官建辉,唐春燕.老年性缺血性脑卒中后抑郁干预治疗对神经功能恢复的疗效分析[J].医学信息,2019,32(03):125.[doi:10.3969/j.issn.1006-1959.2019.03.040]
　SHANGGUAN Jian-hui,TANG Chun-yan.Effect of Intervention Therapy on Neurologic Function Recovery after Senile Ischemic Cerebral Apoplexy[J].Medical Information,2019,32(17):125.[doi:10.3969/j.issn.1006-1959.2019.03.040]
[2]宫园园.LDL、Hcy、D-二聚体及颈动脉粥样硬化与急性缺血性脑卒中相关性研究[J].医学信息,2019,32(05):117.[doi:10.3969/j.issn.1006-1959.2019.05.036]
　GONG Yuan-yuan.Correlation between LDL,Hcy,D-dimer and Carotid Atherosclerosis and Acute Ischemic Stroke[J].Medical Information,2019,32(17):117.[doi:10.3969/j.issn.1006-1959.2019.05.036]
[3]梁道博,姚卜飞,夏双燕.氯吡格雷联合阿司匹林治疗急性冠脉综合征疗效与 安全性的Meta分析[J].医学信息,2019,32(11):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
　LIANG Dao-bo,YAO Bu-fei,XIA Shuang-yan.Meta-analysis of the Efficacy and Safety of Clopidogrel Combined with Aspirin in the Treatment of Acute Coronary Syndrome[J].Medical Information,2019,32(17):76.[doi:10.3969/j.issn.1006-1959.2019.11.021]
[4]褚春沐.雷贝拉唑治疗进展性缺血性脑卒中的价值[J].医学信息,2022,35(14):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
　CHU Chun-mu.Value of Rabeprazole in Treatment of Progressive Ischemic Stroke[J].Medical Information,2022,35(17):122.[doi:10.3969/j.issn.1006-1959.2022.14.030]
[5]张利山.缺血性脑卒中后癫痫发作的临床特点及治疗研究[J].医学信息,2019,32(18):38.[doi:10.3969/j.issn.1006-1959.2019.18.013]
　ZHANG Li-shan.Study on the Clinical Features and Treatment of Seizures after Ischemic Stroke[J].Medical Information,2019,32(17):38.[doi:10.3969/j.issn.1006-1959.2019.18.013]
[6]张志颖.老年女性内源性循环雌二醇和卒中风险的研究[J].医学信息,2019,32(22):84.[doi:10.3969/j.issn.1006-1959.2019.22.025]
　ZHANG Zhi-ying.Study on Endogenous Circulating Estradiol and Stroke Risk in Elderly Women[J].Medical Information,2019,32(17):84.[doi:10.3969/j.issn.1006-1959.2019.22.025]
[7]王 焕.替格瑞洛在氯吡格雷抵抗AMI患者PCI术后抗血小板治疗中的应用[J].医学信息,2019,32(24):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
　WANG Huan.Application of Ticagrelor in the Antiplatelet Therapy of Clopidogrel in Patients with AMI after PCI[J].Medical Information,2019,32(17):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
[8]刘廷胜.氯吡格雷联合阿司匹林治疗急性心肌梗死的研究[J].医学信息,2020,33(06):59.[doi:10.3969/j.issn.1006-1959.2020.06.018]
　LIU Ting-sheng.A Study of Clopidogrel Combined with Aspirin in the Treatment of Acute Myocardial Infarction[J].Medical Information,2020,33(17):59.[doi:10.3969/j.issn.1006-1959.2020.06.018]
[9]栾学冰.拜阿斯匹林、那曲肝素联合氯吡格雷治疗急性ST段抬高型心肌梗死疗效[J].医学信息,2020,33(09):136.[doi:10.3969/j.issn.1006-1959.2020.09.043]
　LUAN Xue-bing.The Efficacy of Bayaspirin,Naltreparin Combined with Clopidogrel in the Treatment of Acute ST-segment Elevation Myocardial Infarction[J].Medical Information,2020,33(17):136.[doi:10.3969/j.issn.1006-1959.2020.09.043]
[10]刘 楠.阿司匹林联合氯吡格雷双抗血小板治疗脑梗死的疗效观察及对血清hs-CRP及D-D水平的影响[J].医学信息,2022,35(19):82.[doi:10.3969/j.issn.1006-1959.2022.19.022]
　LIU Nan.The Effect of Aspirin Combined with Clopidogrel Dual Antiplatelet Therapy on Cerebral Infarction and its Effect on Serum hs-CRP and D-D Levels[J].Medical Information,2022,35(17):82.[doi:10.3969/j.issn.1006-1959.2022.19.022]

更新日期/Last Update: 1900-01-01